• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: SIEMENS HEALTHCARE DIAGNOSTICS, INC. ADVIA CENTAUR XP PSA; PROSTATE SPECIFIC ANTIGEN ASSAY (PSA)

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

SIEMENS HEALTHCARE DIAGNOSTICS, INC. ADVIA CENTAUR XP PSA; PROSTATE SPECIFIC ANTIGEN ASSAY (PSA) Back to Search Results
Model Number N/A
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problem No Known Impact Or Consequence To Patient (2692)
Event Date 11/06/2017
Event Type  malfunction  
Manufacturer Narrative
A siemens field service engineer (fse) was sent to the customer site.The fse performed a total service call and no issues were identified.The instrument was then calibrated with all new advia centaur psa lot 281 material and the mcms passed indicating lot 281 is performing as intended.The patient correlations after service and with all new advia centaur psa lot 281 material were acceptable to the customer.The cause of the high bias the customer originally had with the advia centaur psa lot 281 cannot be determined since new material was used after the instrument was serviced.Based on the available information, the advia centaur psa lot 281 is performing as intended.The cause for the discordant advia centaur xp psa results is unknown.The instrument is performing within specification.No further evaluation of the device is required.The ifu states in the limitations section: "note: do not interpret levels of psa as absolute evidence of the presence or the absence of malignant disease.Before treatment, patients with confirmed prostate carcinoma frequently have levels of psa within the range observed in healthy individuals.Elevated levels of psa can be observed in patients with nonmalignant diseases.Measurements of psa should always be used in conjunction with other diagnostic procedures, including information from the patient's clinical evaluation.".
 
Event Description
Discordant high advia centaur xp psa results were obtained for samples from three patients when correlating reagent lot 277 and 281.Patient treatment was not prescribed or altered.There was no report of adverse health consequences due to the discordant psa result.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
ADVIA CENTAUR XP PSA
Type of Device
PROSTATE SPECIFIC ANTIGEN ASSAY (PSA)
Manufacturer (Section D)
SIEMENS HEALTHCARE DIAGNOSTICS, INC.
511 benedict avenue
tarrytown NY 10591 5097
Manufacturer (Section G)
SIEMENS HEALTHCARE DIAGNOSTICS, INC.
333 coney street
walpole MA 02032
Manufacturer Contact
eiman sulieman
333 coney street
e. walpole, MA 02032
5086604603
MDR Report Key7067599
MDR Text Key93881962
Report Number1219913-2017-00227
Device Sequence Number1
Product Code MTG
UDI-Device Identifier00630414202990
UDI-Public00630414202990
Combination Product (y/n)N
Reporter Country CodeUS
PMA/PMN Number
P950021
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type health professional,user faci
Reporter Occupation Other Health Care Professional
Type of Report Initial
Report Date 11/29/2017
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? No
Is this a Product Problem Report? Yes
Device Operator Health Professional
Device Expiration Date05/03/2018
Device Model NumberN/A
Device Catalogue Number10310293
Device Lot Number89916281
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Was the Report Sent to FDA? No
Initial Date Manufacturer Received 11/06/2017
Initial Date FDA Received11/29/2017
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Is the Device Single Use? No
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
-
-